Abstract. New technologies to generate high-dimensional data provide unprecedented opportunities for unbiased identification of biomarkers that can be used to optimize pre-operative planning, with the goal of avoiding costly postoperative complications and prolonged hospitalization. To identify such markers, we studied the global gene expression profiles of three organs central to the metabolic and inflammatory homeostasis isolated from coronary artery disease (cAd) patients during coronary artery bypass grafting (cABG) surgery. A total of 198 whole-genome expression profiles of liver, skeletal muscle and visceral fat from 66 cAd patients of the Stockholm Atherosclerosis Gene Expression (STAGE) cohort were analyzed. Of ~50,000 mRNAs measured in each patient, the mRNA levels of the anti-inflammatory gene, dualspecificity phosphatase-1 (DUSP1) correlated independently with post-operative stay, discriminating patients with normal (≤8 days) from those with prolonged (>8 days) hospitalization (p<0.004). To validate dUSP1 as a marker of risk for post-operative complications, we prospectively analyzed 181 patients undergoing cABG at Tartu University Hospital for dUSP1 protein levels in pre-operative blood samples. The pre-operative plasma levels of dUSP1 clearly discriminated patients with normal from those with prolonged hospitalization (p=2x10 -13
Introduction
New technologies to generate genome-wide molecular activity measurements, in combination with systems analyses of biological data, allow for a more complete understanding of the molecular interactions underlying complex diseases such as coronary artery disease (cAd) (1) . The assembled databases can also be used to identify molecular biomarkers to predict disease development and responses to therapies and interventions (2) . Surgical procedures pose a risk for post-operative morbidity. Moreover, these procedures are expensive as is the post-operative care. From the perspective of the healthcare economy as well as the well-being of the individual patient, identifying markers to predict the risk for post-operative complications is desirable.
coronary artery bypass grafting (cABG) is a safe, widely used procedure to revascularize the myocardium in patients with obstructive cAd; however, it is associated with an increased risk of post-operative morbidities. For example, cAd patients with diabetes mellitus have an increased risk of morbidity and mortality after cABG (3) (4) (5) (6) (7) , as do hyperglycemic patients without a clinical diagnosis of diabetes (7, 8) .
Since only a fraction of cABG patients also have diabetes, a more generally useful but specific predictor of the increased risk for prolonged post-operative stay due to morbidity after cABG would be of great clinical value. Patients at increased Blood levels of dual-specificity phosphatase-1 independently predict risk for post-operative morbidities causing prolonged hospitalization after coronary artery bypass grafting (9) . From this cohort, we identified dualspecificity phosphatase-1 (DUSP1) as an independent marker of post-operative morbidities and hospital stay. Then, in a prospective validation study of 181 cABG patients, preoperative dUSP1 plasma levels clearly discriminated patients who suffered post-operative morbidities leading to prolonged stay from those who had uncomplicated, normal postoperative stay.
Materials and methods
Patient selection. The STAGE cohort (9) was used to examine hospitalization or rehabilitation days in cABG patients. In brief, 124 patients undergoing cABG at the karolinska University Hospital, Solna, were recruited. The exclusion criteria were the presence of other active severe diseases (e.g., cancer, kidney disease, and chronic systemic inflammatory diseases). The STAGE study was approved by the hospital's ethics committee. To validate the findings, we collected preoperative blood samples from 250 patients undergoing cABG at the Tartu University Hospital; approval was obtained from the ethics committees at Tartu University Hospital (Ethics Review committee on Human Research) and in Stockholm (Etisk prövningsnämnd, Stockholm). All patients gave written informed consent. Fifty-two Tartu patients were excluded because they had prolonged post-operative hospital stays for reasons not directly linked to the surgery (e.g., social or mental, n=38) or left the hospital early despite complications related to surgery (n=7) or because blood samples were mistakenly drawn after surgery (n=7), leaving a total of 198 patients. Tissue samples were collected during cABG by four surgeons at karolinska Hospital and three at Tartu University Hospital, who followed a strict protocol that mandated biopsy collection at specific time-points during the CABG surgery. Anesthesia was standardized; systolic blood pressure was kept at <150 mmHg. Biopsies were obtained from the skeletal muscle, visceral mediastinal fat and the anterior hepatic edge (liver) through a small incision in the diaphragm, preserved in RNAlater (Qiagen), and frozen at -80˚C.
Patient characterization. Using a standard questionnaire, a research nurse obtained a medical history and information on lifestyle factors (e.g., smoking, alcohol consumption, and physical activity) from 114 STAGE patients (9) 3 months after surgery and from the Tartu cohort before the surgery. All patients underwent a physical examination, and venous blood samples were drawn into precooled sterile tubes (vacutainer, Becton-dickinson) containing sodium EdTA and placed on ice. Plasma was recovered within 30 min by centrifugation (2,750 x g, 20 min, 4˚C) for analysis of cholesterol, triglyceride and lipoproteins as previously described (10) . Blood glucose was measured by a glucose oxidation method (kodak Ektachem). In the STAGE cohort, fasting blood glucose was determined before anesthesia on the morning of surgery from whole blood by the glycodehydrogenase method (Hemocue; Ängelholm, Sweden). At karolinska and Tartu Hospitals, all cABG patients were allowed to stay for 8 days after surgery regardless of their physical conditions. Longer hospital stays were based on the individual status of the patients. Questionnaires to assess post-operative health-related quality of life were mailed to the STAGE patients on average 3.3 years (range 2.7-4.3 years) after surgery.
Gene expression profiling in STAGE. RNA was isolated from the biopsies with TRIzol (BRL-Life Technologies) and FastPrep (MP Biomedicals), purified with the RNeasy Mini kit (Qiagen) with a dNase1 treatment step (Qiagen). Sample quality was assessed with the Agilent Bioanalyzer 2100. cRNA yield was assessed with a spectrophotometer (Nd-1000, Nanodrop Technologies) before hybridization to HG-U133 Plus 2.0 arrays (Affymetrix). The arrays were processed with a Fluidics Station 450, scanned with a GeneArray Scanner 3000, and analyzed with the Genechip Operational software 2.0.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
For cdNA synthesis, 150 ng of total RNA was reverse transcribed with Superscript III (Invitrogen) according to the manufacturer's protocol. After a 4-fold dilution, cdNA (3 µl) was amplified by real-time PCR with 1X TaqMan universal PcR master mix (Applied Biosystems) on an ABI Prism 7000 (PE Biosystems) with software according to the manufacturer's protocol. Assay-On-demand kits containing corresponding primers and probes from Applied Biosystems were used, and expression values were normalized to acidic ribosomal phosphoprotein P0. Each sample was analyzed in duplicate.
Enzyme-linked immunosorbent assay (ELISA).
Plasma concentrations of dUSP1 in blood samples from patients in Tartu were determined by ELISA. Wells were coated overnight at 4˚C with 100 µl of diluted (1 µg/l) capture antibody (dUSP1; M-18, Santa cruz Biotechnology). After washing and blocking, samples were incubated with biotinylated antibody (M-18; 1:400). Streptavidin-horseradish peroxidase (R&d Systems) and 3,3',5,5'-tetramentylbenzidine (TMB) (Invitrogen) were used for detection. In 17 of 198 blood samples, plasma proteins had degenerated, and dUSP1 levels could not be determined, leaving a total of 181 dUSP1 measurements.
Statistical analyses. clinical and metabolic characteristics are given as continuous variables with the means and Sd or as categorical variables with numbers and percentages of subjects. Gene expression values were pre-processed with Quantile Normalization and the Robust Multichip Average (11) . Of 604,258 perfect-match Affymetrix probe signals, 280,523 could be mapped to 16,685 Entrez genes without using cross-hybridizing probes. P-values were calculated for continuous variables with unpaired t-tests; skewed values were log-transformed. Spearman rank correlation was used for correlation analysis; p-values were determined by a t-test after a Fisher transformation. Mathematica 5.1 or Statview 5.0.1 were used for all calculations.
Results

CABG morbidities causing prolonged hospitalization in STAGE patients.
The characteristics of the STAGE cohort are shown in Table I . Their age, gender distribution, and drug therapy were typical for cABG cohorts. The most frequent reason for prolonged hospitalization (>8 days) was atrial fibrillation, followed by post-operative infections, bleeding, kidney failure, stroke, and pneumothorax (Fig. 1) . Of the 37 patients with prolonged hospitalization, all but 4 had at least one of these cABG morbidities (Fig. 1) , suggesting that the reasons for prolonged hospitalization were directly linked to complications of cABG.
The duration of the post-operative stay did not correlate with any of the clinical characteristics of the patients (Table I) , although trends were observed for age at surgery (r 2 =0.21; p=0.09) and pre-operative fasting blood glucose levels (r 2 =0.24; p=0.06). The borderline significance of the correlation with fasting blood glucose levels is consistent with previous studies that diabetics undergoing cABG suffer more post-operative morbidities, leading to prolonged hospitalization (3, 7, 8, 12, 13) . Importantly, post-operative stay did not correlate with the extent of coronary stenosis, as judged from pre-operative angiograms (not shown).
Markers of post-operative morbidities leading to prolonged hospitalization in the STAGE cohort. We first analyzed the STAGE gene expression compendium to seek changes in gene activity in the liver, skeletal muscle, and visceral fat that could predict cABG patients at risk of a prolonged post-operative stay, either adding days for rehabilitation ('rehabilitation') or not ('hospitalization'). To this end, we examined the correlations between the days of post-operative stay and mRNA levels obtained from each of the three tissues. Many of the correlated genes were related to immune or inflammatory processes (Table II) . This is not surprising since the most common post-operative morbidities are associated with inflammatory processes (14, 15) .
DUSP1 had the highest correlation with rehabilitation days (r 2 =0.44), together with the major histocompatibility class II, dO β (HLA-dOB) in the liver (r 2 =-0.45). However, in contrast to HLA-dOB the correlation with DUSP1 was validated by RT-PcR (Fig. 2) . In a stepwise regression analysis, the correlation with DUSP1 was shown to be independent of fasting blood glucose levels and patient age. Interestingly, dUSP1 has previously been highlighted as an early marker of the inflammatory processes and has also been associated with the extent of carotid atherosclerosis (16-19).
We next examined the DUSP1 mRNA levels in patients with normal (≤8 days) and prolonged (>8 days) rehabilitation and hospitalization. As shown in Fig. 2 DUSP1 mRNA levels were clearly elevated in patients with prolonged rehabilitation (p<0.003, Fig. 2A) as well as hospitalization (p<0.004,  Fig. 2B ). RT-PCR confirmed the difference in DUSP1 mRNA levels between patients with normal and prolonged rehabilitation and hospitalization ( Fig. 2c and d) .
Validation of DUSP1 as a biomarker of post-operative complications and hospitalization. Of ~17,000 genes examined in three separate tissues in the STAGE cohort, DUSP1 mRNA levels were the strongest predictor of post-operative complications and subsequent hospitalization. Although this observation was confirmed by RT-PCR, the relation between DUSP1 and the post-operative stay may still be a chance observation, given the multiple testing performed (3 x 17,000). Furthermore, the gene expression in skeletal muscle is not a feasible biomarker although the tissue is easily obtained. Therefore, in order to validate the correlations between the post-operative hospitalization and DUSP1 levels in the STAGE cohort, we prospectively collected pre-operative blood samples from patients undergoing elective cABG at the Tartu University Hospital and measured dUSP1 by ELISA. The distribution of hospital days in the Tartu cohort was similar to that in the STAGE cohort (data not shown). dUSP1 blood levels clearly separated patients with ≤8 hospital days from those with >8 days (Fig. 3A) . The levels of C-reactive protein (cRP) in pre-operative blood also differed between these groups but with much lower statistical significance (Fig. 3B) . These results were also reflected in the odd ratios: 5.1 for DUSP1 [confidence interval (CI), 3.0-8.5; p<0.0001] and 1.4 for cRP (cI, 1.1-1.8; p=0.003) (Fig. 3c) . To test the discriminative power of dUSP1 plasma levels to sort patients into groups of prolonged and normal hospitalization times, a receiver operating characteristic (ROc) curve was established based on DUSP1 sensitivity and specificity (Fig. 3D) . At a dUSP1 threshold of 0.25 ng/ml, the ROc curve was clearly displaced toward the upper left corner, and the area under the curve was 0.80. The ROc curve data indicate that this threshold of dUSP1 plasma concentration can be used to identify patients at increased risk of morbidities leading to prolonged hospitalization after cABG.
Discussion
In this study, analysis of gene expression profiles of liver, skeletal muscle, and visceral fat isolated from 66 STAGE patients during CABG identified the anti-inflammatory gene, dUSP1 as an independent marker of post-operative morbidities leading to prolonged hospitalization. The predictive value of dUSP1 was validated in a prospective study of 181 cABG patients. In that analysis, patients with post-operative complications leading to a prolonged hospital stay had higher pre-operative blood levels of dUSP1 than those who had no complications events and a normal post-operative stay (p<2x10 -13 ). The ROc curve indicated that the plasma levels of dUSP1 can serve as a diagnostic test for the risk of postcABG morbidities leading to prolonged hospitalization.
A rising trend in recent decades has been to shorten in-hospital care in favor of health economy savings (20) . This trend has perhaps had an adverse effect on these patients who actually need more careful pre-operative preparations and post-operative care. The savings from curtailing in-hospital care may easily be offset by the increased cost for postoperative complications in a few patients. Ideally, patients at increased risk of post-operative complications should be identified before surgery. This would be of great benefit for the individual patient and to health economy. diabetics who undergo surgery are at increased risk of post-operative complications (3, 4, 7, 8, 12, 13) , most likely because of increased inflammation both systemically (21) and in the arterial wall (22) . Other markers that can detect early signs of inflammation would be of great value.
currently, besides biomarkers of general health status (i.e., age, gender, smoking status, and cholesterol and glucose levels), the only established predictor of inflammation in clinical use is CRP. Other inflammatory markers that are not routinely used in the clinic are interleukins (23), lipoprotein-associated phospholipase A2 and myeloperoxidase (24) . Our findings suggest that the anti-inflammatory gene DUSP1, previously identified in a screen for blood markers of atherosclerosis (16, 25) can be used as a complement to these markers, or possibly by itself, to help identify patients at increased risk of post-operative complications after vascular surgery.
Located on chromosome 5q34, DUSP1 is a highly conserved gene that encodes a 39 kda protein expressed in the nucleus. As its name implies, DUSP1 has a dual specificity for tyrosine and threonine and inactivates mitogen-activated protein kinases (MAPks) (26) . MAPks are part of a phosphorylation signaling pathway that induces a cascade of genes that trigger innate immune responses (17) . Regulation of these genes at the transcriptional and post-transcriptional level by dUSP1 affects cell proliferation and differentiation as well as apoptosis. The MAPk pathway has a negative feedback loop that up-regulates dUSP1 in response to pro-inflammatory stimuli, such as oxidative stress and cytokine secretion (27, 28) . dUSP1 has been studied in relation to several cancers and independently predicts outcome of carcinomas (29, 30) . dUSP1 expression is also induced in patients after cardiopulmonary bypass (19, 31) . The tight regulation of dUSP1 expression is possibly necessary because minor differences appear to have substantial impact on the magnitude of inflammatory reactions. Accordingly, the level of dUSP1 expression varies with the severity of the disease state, such as in tumor cells, carcinomas, and chronic inflammatory diseases in humans (19, (27) (28) (29) (30) (31) . This variation in dUSP1 expression probably reflects its tight transcriptional regulation, which further supports the notion that dUSP1 is an important regulator of the innate immune response to inflammation.
In summary, we identified dUSP1, a blood marker of subtle inflammation, as a potential biomarker of morbidities after invasive surgery resulting in prolonged hospitalization. In support of this notion, atrial fibrillation and infections, the major causes of post-operative complications in cABG patients, are both related to inflammation (15, 32) . Our findings provide a strong rationale for measuring blood levels of dUSP1 to predict post-operative complications and a prolonged hospital stay and merit further evaluation in larger longitudinal studies.
